Weijun Biotechnology (00660) announced annual results with profit attributable to shareholders of HK$7.205 million and resumed trading on November 16

According to the Zhitong Finance App, Weijun Biotechnology (00660) announced its annual results for the year ended June 30, 2026, with revenue of HK$405 million, up 7.3% year on year; profit attributable to company owners was HK$7.205 million, with a loss of HK$146.23 million for the same period last year; basic profit per share was HK$3.40 cents.

The shift in earnings from loss to profit for the period was mainly due to the return of impairment losses on property, plant and equipment in the current year. The increase in revenue was mainly driven by an increase in customers and orders this year.

Furthermore, the company has applied to the Stock Exchange, and trading of the company's shares will resume on the Stock Exchange from 9:00 a.m. on November 16, 2026.